NANOBIOTIX Executes Definitive Agreement to Restructure Existing Loan With the European Investment Bank
PARIS and CAMBRIDGE, Mass., Oct. 18, 2022 (GLOBE NEWSWIRE) — NANOBIOTIX (Euronext:NANO –– NASDAQ:NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced execution of a final agreement with the European Investment Bank (“EIB”) to re-align approximately €30.7 million in outstanding debt obligations with the Company’s expected development and commercialization timelines. Nanobiotix previously announced agreement-in-principle with EIB for this restructuring on September 12th, 2022.
Related news for (NBTX)
- Nanobiotix participera à la 6ème conférence annuelle de Biotechnologie de Guggenheim
- Nanobiotix annonce l’atteinte des conditions pour un paiement d’étape de développement de 20 M$ lié à l’étude mondiale de phase 3 en cours sur le cancer de la tête et du cou
- INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
- INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
- Voting Rights and Shares Capital of the Company